Key points are not available for this paper at this time.
Our case demonstrates that tislelizumab combined with sunitinib exhibits potential benefits for patients with advanced RCC, particularly in regions where access to standard combination therapy is limited. However, further clinical evidence is needed to support its widespread adoption in routine clinical practice.
Liu et al. (Sun,) studied this question.